No Data
No Data
Abbisko Cayman NSCLC Drug Gets NMPA's Approval for Clinical Trials
HK Stock Market News | WuXi Biologics-B (02256) surged over 6% as the new generation EGFR inhibitor ABK3376 has been approved for clinical trials.
Hoyo-B (02256) rose more than 6%, as of the time of publication, it rose by 5.76%, closing at 3.49 Hong Kong dollars, with a turnover of 2.2533 million Hong Kong dollars.
Wu Yu-B (02256.HK): ABK3376 has been approved by the National Medical Products Administration for IND.
On September 24th, GeLongHui announced that its subsidiary shanghai allist pharmaceuticals co., ltd. ("HEYU MEDICINE") announced the independent discovery and collaborative research and development of a new generation of EGFR oral small molecule inhibitor ABK3376 with shanghai allist pharmaceuticals co., ltd. The drug has been approved by the China National Medical Products Administration to conduct the first phase I clinical trial in humans for the treatment of non-small cell lung cancer with EGFR-C797S resistance mutation. This is a voluntary announcement made by the company. The group cannot guarantee that ABK3376 will ultimately be successfully approved for marketing.
Express News | Abbisko Cayman Ltd - Abk3376 Obtained Ind Approval From Nmpa
ABBISKO-B: 2024 INTERIM REPORT
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for
No Data
No Data